Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations

References

• Brems DN Alter LA Beckage MJ Altering the association properties of insulin by amino acid replacement Protein Eng 1992 5 6 527 533 1438163
   PubMedGoogle Scholar
• Howey DC Bowsher RR Brunelle RL Woodworth JR Lys(B28), pro(B29)-human insulin. A rapidly absorbed analogue of human insulin Diabetes 1994 43 3 396 402 8314011
   PubMed Web of Science ®Google Scholar
• Oiknine R Bernbaum M Mooradian AD A critical appraisal of the role of insulin analogues in the management of diabetes mellitus Drugs 2005 65 3 325 340 15669878
   PubMed Web of Science ®Google Scholar
• Kurtzhals P Schaffer L Sorensen A Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 2000 49 6 999 1005 10866053
   PubMed Web of Science ®Google Scholar
• Hedman CA Lindstrom T Arnqvist HJ Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes Diabetes Care 2001 24 6 1120 1121 11375381
   PubMed Web of Science ®Google Scholar
• von Mach MA Brinkmann C Hansen T Weilemann LS Beyer J Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers Exp Clin Endocrinol Diabetes 2002 110 8 416 419 12518253
   PubMed Web of Science ®Google Scholar
• Plank J Wutte A Brunner G A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes Diabetes Care 2002 25 11 2053 2057 12401756
   PubMed Web of Science ®Google Scholar
• Homko C Deluzio A Jimenez C Kolaczynski JW Boden G Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects Diabetes Care 2003 26 7 2027 2031 12832307
   PubMed Web of Science ®Google Scholar
• Chao M Wang W Zhang Y Lu X Meng J Ning G Bioequivalence between two human insulin analogs in chinese population: glulisine and lispro Endocrine 2010 38 1 48 52 20960101
   PubMed Web of Science ®Google Scholar
• Heise T Nosek L Spitzer H Insulin glulisine: a faster onset of action compared with insulin lispro Diabetes Obes Metab 2007 9 5 746 753 17593235
   PubMed Web of Science ®Google Scholar
• Radziuk JR Bradley B Welsh L De Felippis Roach P Neutral protamine lispro: Activity profile of s.c. administration with and without admixture of soluble lispro (Abstr 849) Diabetologia 1996 39 1 Suppl 1 A224
   Google Scholar
• Roach P Woodworth JR Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures Clin Pharmacokinet 2002 41 13 1043 1057 12403642
   PubMed Web of Science ®Google Scholar
• Heise T Weyer C Serwas A Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin Diabetes Care 1998 21 5 800 803 9589244
   PubMed Web of Science ®Google Scholar
• Slieker LJ Sundell K Modifications in the 28–29 position of the insulin B-chain alter binding to the IGF-I receptor with minimal effect on insulin receptor binding. (Abstr 670) Diabetes 1991 40 Suppl 1 168A
   Google Scholar
• Slieker LJ Brooke GS Chance RE Insulin and IGF-I analogs: Novel approaches to improved insulin pharmacokinetics Current Directions in Insulin-Like Growth Factor Research, in Advances in Experimental Medicine and Biology LeRoith D Raizada MK 1994 343 25 32
   Google Scholar
• Monnier L Lapinski H Colette C Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c) Diabetes Care 2003 26 3 881 885 12610053
   PubMed Web of Science ®Google Scholar
• Heinemann L Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995 12 5 449 450 7648813
   PubMed Web of Science ®Google Scholar
• Anderson JHJr Brunelle RL Koivisto VA Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group Diabetes 1997 46 2 265 270 9000704
   PubMed Web of Science ®Google Scholar
• Pfutzner A Kustner E Forst T Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes Exp Clin Endocrinol Diabetes 1996 104 1 25 30 8750567
   PubMed Web of Science ®Google Scholar
• Brunelle BL Llewelyn J Anderson JHJr Gale EA Koivisto VA Meta- analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes Diabetes Care 1998 21 10 1726 1731 9773738
   PubMed Web of Science ®Google Scholar
• Raskin P Guthrie RA Leiter L Riis A Jovanovic L Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes Diabetes Care 2000 23 5 583 588 10834413
   PubMed Web of Science ®Google Scholar
• Gough SC A review of human and analogue insulin trials Diabetes Res Clin Pract 2007 77 1 1 15 17112621
   PubMed Web of Science ®Google Scholar
• Gale EA A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. The UK Trial Group Diabet Med 2000 17 3 209 214 10784225
   PubMed Web of Science ®Google Scholar
• Altuntas Y Ozen B Ozturk B Comparison of additional metforminutes or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure Diabetes Obes Metab 2003 5 6 371 378 14617222
   PubMed Web of Science ®Google Scholar
• Bastyr EJ3rd Stuart CA Brodows RG Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ study group Diabetes Care 2000 23 9 1236 1241 10977012
   PubMed Web of Science ®Google Scholar
• Bastyr EJ3rd Johnson ME Trautmann ME Anderson JHJr Vignati L Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure Clin Ther 1999 21 10 1703 1714 10566566
   PubMed Web of Science ®Google Scholar
• Siebenhofer A Plank J Berghold A Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus Cochrane Database Syst Rev 2006 2 CD003287 16625575
   PubMedGoogle Scholar
• Garg S Ampudia-Blasco FJ Pfohl M Rapid-acting insulin analogues in basal-bolus regimens in type 1 diabetes mellitus Endocr Pract 2010 16 3 486 505 20150026
   PubMed Web of Science ®Google Scholar
• Hermansen K Fontaine P Kukolja KK Peterkova V Leth G Gall MA Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes Diabetologia 2004 47 4 622 629 15298338
   PubMed Web of Science ®Google Scholar
• Ashwell SG Amiel SA Bilous RW Improved glycaemic control with insulin glargine plus insulin lispro: A multicentre, randomized, cross-over trial in people with type 1 diabetes Diabet Med 2006 23 3 285 292 16492212
   PubMed Web of Science ®Google Scholar
• Murphy NP Keane SM Ong KK Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens Diabetes Care 2003 26 3 799 804 12610040
   PubMed Web of Science ®Google Scholar
• Heller SR Amiel SA Mansell P Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. UK Lispro Study Group Diabetes Care 1999 22 10 1607 1611 10526722
   PubMed Web of Science ®Google Scholar
• Garg SK Anderson JH Gerard LA Impact of insulin lispro on HbA1c values in insulin pump users Diabetes Obes Metab 2000 2 5 307 311 11225746
   PubMed Web of Science ®Google Scholar
• Raskin P Holcombe JH Tamborlane WV A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump J Diabetes Complications 2001 15 6 295 300 11711322
   PubMed Web of Science ®Google Scholar
• Bode B Weinstein R Bell D Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: A randomized study in type 1 diabetes Diabetes Care 2002 25 3 439 444 11874927
   PubMed Web of Science ®Google Scholar
• Renner R Pfutzner A Trautmann M Harzer O Sauter K Landgraf R Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group Diabetes Care 1999 22 5 784 788 10332682
   PubMed Web of Science ®Google Scholar
• Melki V Renard E Lassmann-Vague V Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps Diabetes Care 1998 21 6 977 982 9614617
   PubMed Web of Science ®Google Scholar
• Attia N Jones TW Holcombe J Tamborlane WV Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM Diabetes Care 1998 21 5 817 821 9589247
   PubMed Web of Science ®Google Scholar
• Guerra YS Lacuesta EA Yrastorza R Miernik J Shakya N Fogelfeld L Insulin injections in relation to meals in the hospital medicine ward: Comparison of 2 protocols Endocr Pract 2011 17 5 737 746 21454236
   PubMed Web of Science ®Google Scholar
• Bartolo PD Pellicano F Scaramuzza A Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes Diabetes Technol Ther 2008 10 6 495 498 19049379
   PubMed Web of Science ®Google Scholar
• Thethi TK Rao A Kawji H Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion J Diabetes Complications 2010 24 2 73 78 19395280
   PubMed Web of Science ®Google Scholar
• Hermansen K Colombo M Storgaard H Ostergaard A Kolendorf K Madsbad S Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes Diabetes Care 2002 25 5 883 888 11978685
   PubMed Web of Science ®Google Scholar
• Dreyer M Prager R Robinson A Efficacy and safety of insulin glulisine in patients with type 1 diabetes Horm Metab Res 2005 37 11 702 707 16308840
   PubMed Web of Science ®Google Scholar
• Philotheou A Arslanian S Blatniczky L Peterkova V Souhami E Danne T Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes Diabetes Technol Ther 2011 13 3 327 334 21291333
   PubMed Web of Science ®Google Scholar
• van Bon AC Bode BW Sert-Langeron C DeVries JH Charpentier G Insulin glulisine compared with insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial Diabetes Technol Ther 2011 13 6 607 614 21457066
   PubMed Web of Science ®Google Scholar
• Luzio S Peter R Dunseath GJ Mustafa L Owens DR A comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h period Diabetes Res Clin Pract 2008 79 2 269 275 18164094
   PubMed Web of Science ®Google Scholar
• Mattoo V Milicevic Z Malone JK A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan Diabetes Res Clin Pract 2003 59 2 137 143 12560163
   PubMed Web of Science ®Google Scholar
• Coscelli C Iacobellis G Calderini C Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits Acta Diabetol 2003 40 4 187 192 14740279
   PubMed Web of Science ®Google Scholar
• Herz M Arora V Campaigne BN Scholtz HE Potgieter MA Mollentze W Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus S Afr Med J 2003 93 3 219 223 12768948
   PubMed Web of Science ®Google Scholar
• Roach P Yue L Arora V Improved postprandial glycemic control during treatment with humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group Diabetes Care 1999 22 8 1258 1261 10480767
   PubMed Web of Science ®Google Scholar
• Yamada S Watanabe M Kitaoka A Switching from premixed human insulin to premixed insulin lispro: A prospective study comparing the effects on glucose control and quality of life Intern Med 2007 46 18 1513 1517 17878636
   PubMed Web of Science ®Google Scholar
• Roach Koledova E Metcalfe S Hultman C Milicevic Z Romania/Russia Mix25 Study Group Glycemic control with humalog Mix25 in type 2 diabetes inadequately controlled with glyburide Clin Ther 2001 23 10 1732 1744 11726007
   PubMed Web of Science ®Google Scholar
• Malone JK Kerr LF Campaigne BN Sachson RA Holcombe JH Lispro Mixture-Glargine Study Group Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy Clin Ther 2004 26 12 2034 2044 15823767
   PubMed Web of Science ®Google Scholar
• Diamond T Kormas N Possible adverse fetal effect of insulin lispro N Engl J Med 1997 337 14 1009 9312672
   PubMed Web of Science ®Google Scholar
• Durnwald CP Landon MB A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy J Matern Fetal Neonatal Med 2008 21 5 309 313 18446657
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A Brown S Hughes S Vice PA Insulin lispro and regular insulin in pregnancy QJM 2001 94 5 255 260 11353099
   PubMed Web of Science ®Google Scholar
• Aydin Y Berker D Direktor N Is insulin lispro safe in pregnant women: Does it cause any adverse outcomes on infants or mothers? Diabetes Res Clin Pract 2008 80 3 444 448 18359121
   PubMed Web of Science ®Google Scholar
• Blanco CG Ballesteros AC Saladich IG Pla RC Glycemic control and pregnancy outcomes in women with type 1 diabetes mellitus using lispro versus regular insulin: A systematic review and meta-analysis Diabetes Technol Ther 2011 13 9 907 911 21714679
   PubMed Web of Science ®Google Scholar
• Jovanovic L Ilic S Pettitt DJ Metabolic and immunologic effects of insulin lispro in gestational diabetes Diabetes Care 1999 22 9 1422 1427 10480503
   PubMed Web of Science ®Google Scholar
• Rubin RR Peyrot M Quality of life and diabetes Diabetes Metab Res Rev 1999 15 3 205 218 10441043
   PubMed Web of Science ®Google Scholar
• Singh H Quality of life in diabetes Int J Diabetes Dev Ctries 2006 26 1 7 10
   Google Scholar
• Kotsanos JG Vignati L Huster W Health-related quality-of-life results from multinational clinical trials of insulin lispro. assessing benefits of a new diabetes therapy Diabetes Care 1997 20 6 948 958 9167105
   PubMed Web of Science ®Google Scholar
• Grey M Boland EA Tamborlane WV Use of lispro insulin and quality of life in adolescents on intensive therapy Diabetes Educ 1999 25 6 934 941 10711075
   PubMed Web of Science ®Google Scholar
• Cameron CG Bennett HA Cost-effectiveness of insulin analogues for diabetes mellitus CMAJ 2009 180 4 400 407 19221353
   PubMed Web of Science ®Google Scholar
• Hall JA Summers KH Obenchain RL Cost and utilization comparisons among propensity score-matched insulin lispro and regular insulin users J Manag Care Pharm 2003 9 3 263 268 14613470
   PubMedGoogle Scholar
• Chen K Chang EY Summers KH Obenchain RL Yu-Isenberg KS Sun P Comparison of costs and utilization between users of insulin lispro versus users of regular insulin in a managed care setting J Manag Care Pharm 2005 11 5 376 382 15934796
   PubMedGoogle Scholar
• Holleman MD Hoekstrra JBL Insulin Lispro N Engl J Med 1997 337 176 183 9219705
   PubMed Web of Science ®Google Scholar